Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise — but the business models to support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? Find out at Cell & Gene Day 2024, a free virtual event, WATCH ON DEMAND HERE.
Precision will be at this year’s Meeting on the Med, April 9-11, 2023, in Rome, Italy. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Med below:
Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
—
Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET
Speakers:
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET
Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.
Precision’s Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series.
“Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types.” (subscription required):
As clinical trial protocols have become more complex in recent years, institutions are facing new challenges in keeping up with the advancements. In this Q&A, Precision’s Sofia Baig, President of Clinical Solutions, discusses the challenges these institutions are facing, how sites can keep pace with new technologies, and improving efficiency in early and later phase research.
The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside. Precision’s Deb Phippard surveys the landscape in MedCity News.
Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.
Precision will be at this year’s Advanced Therapies Week, January 16 – 19, in Miami, FL. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for advanced therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
You can register for Advanced Therapies Week below:
Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:
· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues
· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities
· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders
· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes